SELLAS Life Sciences Group, Inc. annual report, FY2020

SELLAS Life Sciences Group, Inc. — FY2020 Form 10-K

Reporting period: Fiscal year ended December 31, 2020. This is an annual report, not a standalone fourth-quarter filing. SELLAS is a clinical-stage cancer immunotherapy company with no approved products.

Financial performance and liquidity

Metric	2020	2019
License revenue	$1.9 million	$0
Research and development expense	$9.3 million	$7.3 million
General and administrative expense	$9.6 million	$9.9 million
Operating loss	$17.0 million	$20.0 million
Net loss	$16.8 million	$19.3 million
Net cash used in operating activities	$10.4 million	$17.6 million
Net cash provided by financing activities	$38.4 million	$19.6 million

Revenue was from the 3D Medicines license and technology transfer, not product sales. Of the $7.5 million upfront payment, $1.9 million was recognized in 2020 and $5.6 million remained deferred at year-end. The company also included $2.0 million of development milestones in the initial transaction price; further milestones and royalties remain contingent.
Cash and cash equivalents were $35.3 million at year-end, versus $7.3 million in 2019; restricted cash was $0.1 million. Management expected cash, together with $3.0 million received from warrant exercises after year-end, to fund planned operations for at least 12 months from the financial-statement issuance date. This was not expected to fund completion of development and commercialization.
Total liabilities were $18.1 million, including $4.6 million of contingent consideration and lease liabilities. The filing does not report conventional borrowings as a material debt balance.
SELLAS raised net proceeds of approximately $29.9 million from stock and warrant offerings and received $8.5 million from warrant exercises during 2020. Common shares outstanding rose from 5.08 million at year-end 2019 to 14.25 million at year-end 2020.
No meaningful product gross margin was reported because the company had no product sales. The net loss narrowed partly because 2019 included a $2.8 million non-cash impairment charge for GALE-301/302; R&D spending increased in 2020 as the Phase 3 AML trial began.

Business, developments and outlook

GPS (galinpepimut-S) is the lead WT1-targeting candidate. The Phase 3 REGAL trial in AML maintenance after second remission began in January 2020. The company planned to enroll about 116 patients at up to approximately 135 sites, with an interim safety and futility analysis after 80 deaths, then anticipated in the first half of 2022, subject to enrollment and COVID-19 conditions.
SELLAS reported early, small-cohort combination-study findings in ovarian cancer and mesothelioma during 2020. These are preliminary results, not confirmatory evidence of efficacy. Further data were expected by the end of the first half of 2021.
In December 2020, SELLAS granted 3D Medicines exclusive Greater China rights to GPS and preclinical GPS-Plus. The agreement provides a $7.5 million upfront payment, up to $194.5 million in contingent milestones, and tiered royalties; 3D Medicines is responsible for development and commercialization costs in the territory.
NPS, a HER2-directed candidate, had prior Phase 2 data supporting further study in TNBC. SELLAS had finalized a proposed Phase 3 design but was seeking an out-license to fund and conduct it, and did not plan to fund that trial itself. The company reported that the NPS Phase 2 HER2 3+ study’s primary analysis was expected by the end of 2021.
SELLAS decided to discontinue GALE-301/302 development and entered a termination agreement with the licensors in February 2021. This followed the $2.8 million impairment recorded in 2019.
Management expects continued operating losses and says additional funding will be needed for later development and potential commercialization. COVID-19 had delayed some site activations and enrollment; the company could not reliably quantify the pandemic’s overall financial impact.

Risks, contingencies and notable items

Clinical and regulatory risk is substantial: no candidate is approved, and earlier or preliminary clinical findings may not predict Phase 3 results or regulatory approval. Patient recruitment, especially in the narrow AML second-remission population, may be delayed.
The company depends on third parties for clinical execution and manufacturing, including single-source supply arrangements. COVID-19 or manufacturing interruptions could affect trial supply and timelines.
Liquidity depends on cash, future financing and potential partnerships. Additional equity financing may dilute shareholders; the filing says existing resources are insufficient to complete development and launch activities.
The $4.6 million contingent-consideration liability is a Level 3 fair-value estimate based on milestone probabilities and timing. Up to $30 million of contingent payments remain possible, subject to milestones; payment may be in cash or shares under stated conditions.
Legacy Galena securities class-action and derivative litigation remained pending. The company denied the allegations; a derivative-case settlement was subject to documentation and court approval. Management stated that, as of the filing, any liability for legal matters was not expected to materially affect results, financial position or cash flows, but outcomes remain uncertain.
The independent auditor issued an unqualified opinion on the financial statements. Management concluded internal control over financial reporting was effective; the auditor did not provide an attestation on internal controls because SELLAS qualified for the smaller-reporting-company exemption.

Most important facts for investors to verify

REGAL enrollment pace, site activation, COVID-19 effects and any revisions to the interim-analysis timing.
Whether GPS combination-study findings mature into sufficiently robust, controlled efficacy and safety evidence.
Cash burn and runway versus the company’s stated 12-month operating estimate, and its need and ability to raise additional capital.
3D Medicines’ technology-transfer progress, milestone terms and any subsequent receipts; distinguish recognized revenue from cash received and contingent payments.
NPS out-licensing prospects and the timing and results of its ongoing Phase 2 study.
Potential dilution from outstanding warrants, options, future financings and any share-settled contingent obligations; also monitor the unresolved legacy litigation.